Emerging treatment modalities for the management of diabetes mellitus

D.M.Thorat

Professor& HOD.,Krishna Institute of Medical Sciences,Krishna Vishwa Vidyar.Vpeeth
"Deemed To Be University",Karad –415110,Maharashtra

Dr. A.V.Chavda

Tutor, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth
"Deemed To Be University",Karad –415110,Maharashtra

Dr.A.S.Shah

Tutor, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth
"Deemed To Be University",Karad –415110,Maharashtra

Abstract

A chronic metabolic condition called diabetes mellitus is characterized by high blood glucose levels. Diabetes prevalence is rising quickly over the world, placing a heavy burden on people and healthcare systems. The three mainstays of traditional diabetes treatment are insulin therapy, oral antidiabetic drugs, and lifestyle changes. However, these methods frequently fail to provide the best glycemic control and shield against long-term problems. Therefore, there is a need for cutting-edge therapeutic approaches that can address these problems and enhance diabetes patients' results.

The goal of this review article is to examine recent advancements in the field of diabetes management and to highlight new treatment modalities that could completely transform the way that people with diabetes are treated. Both pharmaceutical and technical developments are highlighted.

The paper covers the importance of novel therapeutic drugs in the pharmacological domain, including glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and incretin-based medicines. These drugs have demonstrated potential in improving glycemic control, lowering cardiovascular risk, and treating diabetes-related comorbidities.

The research examines the possibility of more recent technologies, including as telemedicine, closed-loop insulin delivery devices, and artificial intelligence (AI). Insulin infusion and continuous glucose monitoring are the two components of closed-loop insulin administration systems, commonly referred to as artificial pancreas systems, which offer automatic glucose control. AI and telemedicine present prospects for remote monitoring, early diagnosis of complications, and individualized diabetes care.

This review paper aims to give healthcare professionals and researchers a thorough understanding of the current landscape and future directions in diabetes management by looking at these emerging treatment modalities, their mechanisms of action, clinical efficacy,

and potential benefits. The combination of these cutting-edge techniques with tried-and-true methods may improve diabetes patients' results and quality of life.

Keywords: Diabetes mellitus, Treatment modalities, Emerging therapies, Incretin-based therapies, Sodium-glucose cotransporter 2 (SGLT2) inhibitors

Introduction

A common chronic metabolic illness called diabetes mellitus causes persistent hyperglycemia as a result of problems with insulin secretion, insulin action, or both. Approximately 463 million adults worldwide are believed to have diabetes as of 2019, and by 2045, that figure is expected to increase to 700 million [1]. Worldwide healthcare systems face enormous problems as a result of the huge rise in the prevalence of diabetes, demanding ongoing work to enhance disease management and treatment options.

Diabetes has traditionally been treated with a combination of pharmacological therapies and lifestyle changes, such as dietary adjustments, regular physical activity, and weight management. The cornerstone of treatment for type 2 diabetes has long been oral antidiabetic drugs like metformin, sulfonylureas, and thiazolidinediones, while insulin therapy has remained crucial for people with type 1 diabetes and those with advanced type 2 diabetes. These therapeutic methods have shown effective in regulating blood sugar levels and lowering the risk of problems, but they are not without drawbacks [2-6].

Despite the availability of numerous anti-diabetic drugs, it can be difficult for many people with diabetes to achieve and maintain adequate glycemic control. Subpar results are a result of poor adherence to treatment plans, drug side effects, and the degenerative nature of the illness. Furthermore, long-term diabetes consequences such cardiovascular disease, nephropathy, retinopathy, and neuropathy continue to be very harmful to people's health.

There is a rising focus on examining novel therapy approaches to address these issues and enhance diabetes control. In order to give a comprehensive picture of these most recent developments, this review paper will concentrate on both pharmaceutical and technological breakthroughs. Healthcare practitioners can learn about cutting-edge strategies that might change the diabetes care landscape by analyzing the efficacy, safety, and possible advantages of these developing modalities.

Incretin-based Therapies: Revolutionizing Glycemic Control

Incretin-based medicines, which provide new ways to achieve optimal glycemic control, have recently made strides in the treatment of type 2 diabetes. The digestive hormones known as incretins, which are generated in response to food consumption, are essential for controlling insulin secretion and glucose homeostasis. Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are the two main kinds of incretin-based treatments that have been developed. DPP-4 inhibitors work by blocking the enzyme that hastens the breakdown of incretin hormones produced naturally, including GLP-1 and glucose-dependent insulinotropic peptide (GIP). DPP-4 inhibitors improve these hormones' impact on insulin secretion and reduce glucagon release by lengthening their half-lives, which results in better glycemic control. These medications provide a number of benefits,

such as oral administration, a low risk of hypoglycemia, and weight neutrality. On the other hand, GLP-1 receptor agonists directly activate the GLP-1 receptor, simulating the effects of natural GLP-1. These substances improve glycemic control and may aid in weight loss by increasing glucose-dependent insulin secretion, decreasing glucagon release, delaying stomach emptying, and promoting satiety. GLP-1 receptor agonists come in long-acting and short-acting forms, giving patients a variety of therapy options [1-6].

The effectiveness and safety of incretin-based treatments in attaining glycemic control and lowering hemoglobin A1c levels have been shown in numerous clinical trials. These treatments have also demonstrated other advantages beyond glucose regulation, such as kidney and cardiovascular protection. Both DPP-4 inhibitors and GLP-1 receptor agonists have shown indications of cardiovascular safety and, in some circumstances, cardiovascular benefit in cardiovascular outcomes trials (CVOTs). However, when choosing the ideal incretin-based medication, it's crucial to take into account the unique patient traits, preferences, and comorbidities. To get the best possible treatment outcomes, considerations such renal function, cardiovascular risk profile, gastrointestinal tolerance, and patient adherence should be made. Overall, incretin-based treatments that offer novel modes of action and other advantages beyond glucose control have transformed the management of type 2 diabetes. Further advancements in diabetes treatment options and outcomes may result from continued research and development in this area [6-10].

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Beyond Glycemic Control

A unique family of diabetes drugs that has received a lot of interest recently is the sodium-glucose cotransporter 2 (SGLT2) inhibitors. These medications function by preventing the reabsorption of glucose in the renal tubules, increasing urine glucose excretion, and lowering blood glucose levels as a result. The advantages of SGLT2 inhibitors, however, go beyond glycemic management. The advantages of SGLT2 inhibitors for the cardiovascular and renal systems have been shown by clinical trials and practical experience. The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) research revealed that patients receiving empagliflozin compared to placebo experienced a substantial decrease in cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The Canagliflozin Cardiovascular Assessment Study (CANVAS) program also showed that canagliflozin medication significantly reduced major adverse cardiovascular events [4]. These results have prompted the inclusion of SGLT2 inhibitors in the recommendations for lowering cardiovascular risk in type 2 diabetes patients [11-14].

Additionally, SGLT2 inhibitors have demonstrated renoprotective effects by lowering the likelihood of kidney disease progression, including albuminuria development and the requirement for renal replacement therapy. Trials like the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) experiment [4] showed the effects on renal outcomes. These results show that SGLT2 inhibitors have the ability to alter the course of diabetic kidney disease.

Additionally, SGLT2 inhibitors show positive effects on blood pressure and body weight. These medications are an excellent alternative for people with type 2 diabetes who are overweight or obese since the enhanced urine glucose excretion they cause results in modest

weight loss. Additionally, it has been demonstrated that SGLT2 inhibitors lower both systolic and diastolic blood pressure, adding to their overall cardiovascular advantages. Despite the positive results that SGLT2 inhibitors have produced, there are some serious safety issues that need to be taken into account. These issues include the possibility of vaginal and urinary tract infections, volume depletion, and euglycemic diabetic ketoacidosis. When administering SGLT2 inhibitors, medical practitioners should thoroughly evaluate the patient's features and keep an eye out for these possible side effects. In conclusion, SGLT2 inhibitors have become an important component of the arsenal of anti-diabetic drugs. These medications have benefits for the heart, kidneys, and weight loss in addition to decreasing blood sugar levels. They also help manage blood pressure. Their inclusion in treatment recommendations demonstrates the rising acceptance of their therapeutic advantages. To better understand their long-term safety and effectiveness, more research and post-marketing monitoring are required [15-18].

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Multifaceted Approach to Diabetes Management

For the treatment of diabetes mellitus, glucagon-like peptide-1 (GLP-1) receptor agonists have become a potent therapeutic alternative. These substances imitate the effects of endogenous GLP-1, a hormone that the digestive tract releases in response to the consumption of nutrients. The actions of GLP-1 receptor agonists include increasing glucose-dependent insulin secretion, decreasing glucagon release, delaying stomach emptying, and boosting feelings of satiety. The effectiveness of GLP-1 receptor agonists in establishing glycemic control and lowering hemoglobin A1c levels has been shown in numerous clinical trials and real-world research. In terms of their capacity to meet specific glycemic objectives and maintain weight loss, these medicines have demonstrated advantages over other anti-diabetic drugs [5]. In the historic Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) [6], it was shown that there was a significant decrease in serious adverse cardiovascular events. This cardiovascular advantage has strengthened the function of GLP-1 receptor agonists in the treatment of diabetes [1,9,16-19].

Agonists of the GLP-1 receptor provide advantages beyond glycemic control. They are a good alternative for those with type 2 diabetes who are overweight or obese because they have been linked to weight loss. Additionally, these substances have shown promise for enhancing beta-cell activity, maintaining pancreatic beta-cell bulk, and lowering insulin resistance [5]. These outcomes add to the GLP-1 receptor agonists' multimodal strategy for targeting the underlying pathophysiology of type 2 diabetes. The availability of several formulations and dose options, including once-daily or once-weekly injections, can help patients adhere to GLP-1 receptor agonists. With the extended-release formulations, convenience is increased, and treatment adherence may even be improved. Gastric side effects such nausea and vomiting are safety concerns with GLP-1 receptor agonists, however these usually pass quickly and get better with time. Although infrequently, pancreatitis and thyroid-related adverse effects have been documented. Healthcare practitioners need to be on the lookout for these possible hazards and inform patients about the symptoms and indicators. In conclusion, GLP-1 receptor agonists provide a flexible strategy for managing diabetes.

They give sustained weight loss, efficient glycemic management, cardiovascular advantages, and may alter the pathogenesis of type 2 diabetes. The treatment paradigm for people with type 2 diabetes has incorporated these medications, and current research is advancing our knowledge of their long-term efficacy and safety [19,20].

Advanced Insulin Delivery Systems: The Promise of Closed-Loop Technology

Closed-loop systems, in particular, advanced insulin delivery systems, have drawn a lot of interest in the treatment of diabetes. Closed-loop systems, commonly referred to as artificial pancreas systems, automate glucose regulation by combining continuous glucose monitoring (CGM) technology with insulin infusion. These systems modify insulin delivery based on current glucose measurements in an effort to imitate the physiological insulin response. Compared to conventional insulin administration techniques, closed-loop technology has a number of benefits. It enables more customized and precise insulin administration, lowering the danger of hypo- and hyperglycemia. Closed-loop systems improve glycemic control and lengthen duration in target range by continually monitoring glucose levels and changing insulin supply. Clinical investigations have shown that closed-loop devices are effective and secure for both adults and kids with type 1 diabetes. The Control to Range (CTRo) experiment and the International Diabetes Closed-Loop (iDCL) trial both found that closed-loop systems increased time in range, decreased hypoglycemia episodes, and improved glycemic control [7]. Additionally, closed-loop technology has demonstrated potential advantages in lowering the strain of diabetes-related chores, enhancing quality of life, and lowering the burden of daily living. There are ongoing developments in closed-loop technology, including the creation of fully closed-loop systems that run without user input. These solutions are designed to make using them even simpler and less demanding on diabetics' cognitive abilities [5,15,19].

The cost, accessibility, and user acceptance of closed-loop systems continue to be obstacles to their widespread implementation. Addressing these obstacles will be essential as closed-loop technology develops in order to assure its widespread adoption and accessibility for people with diabetes. In summary, modern insulin delivery systems, especially closed-loop technologies, present a viable strategy for managing diabetes. These devices automate glucose regulation, improve glycemic control, and lower the danger of hypoglycemia. The opportunity exists for further research and development in this area to transform insulin therapy and enhance the lives of people with diabetes.

Conclusion

With the development of new treatment modalities that show tremendous promise in enhancing outcomes for people with diabetes, the management of diabetes mellitus is continuing to change. Incretin-based medicines, sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sophisticated insulin delivery systems, and technical advancements have all been emphasized in this review paper as emerging approaches to managing diabetes.

Dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists are two examples of incretin-based treatments that provide novel mechanisms of action to improve glycemic

control and treat cardiovascular and renal problems brought on by diabetes. In addition to lowering blood glucose levels, SGLT2 inhibitors also show promise for improving kidney and cardiovascular health. GLP-1 receptor agonists offer a variety of advantages, such as glycemic control, weight loss, and maybe beta-cell preservation.

Closed-loop technology, in particular, offers the promise of automated glucose control, easing the load of diabetes self-management and enhancing glycemic results. Advanced insulin delivery devices. Personalized diabetes management, early diagnosis of complications, and remote monitoring are made possible by technological advancements like artificial intelligence (AI) and telemedicine.

Even though these new treatment options have a lot of promise, choosing the best course of action requires careful consideration of each patient's unique traits, preferences, and comorbidities. Accessibility, affordability, and safety issues should also be taken into account.

For the efficacy, safety, and long-term effects of these novel therapy modalities to be further validated, more research, clinical studies, and post-marketing surveillance are required. Healthcare workers can improve patient outcomes, raise quality of life, and lessen the burden of diabetes by combining these cutting-edge treatments with tried-and-true tactics.

As a result, the possibilities for better, more individualized care are opening up thanks to the advances in diabetes management. Healthcare practitioners can work to achieve optimal glycemic control, prevent complications, and enhance the general wellbeing of people with diabetes by keeping up with these new treatment approaches.

References:

1. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. *Int J Clin Pract*. 2006;60(11):1454-1470. doi:10.1111/j.1742-1241.2006.01178.x
2. Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3(3):153-165. doi:10.1016/j.cmet.2006.01.004
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
4. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32(1):193-203. doi:10.2337/dc08-9025
6. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
7. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: A systematic

review and meta-analysis of outpatient randomised controlled trials. The Lancet Diabetes & Endocrinology. 2017;5(7):501-512. doi:10.1016/S2213-8587(17)30187-X

8. Haidar A. Insulin-and-Glucagon Artificial Pancreas Versus Insulin-Alone Artificial Pancreas: A Short Review. Diabetes Spectr. 2019;32(3):215-221. doi:10.2337/ds18-0097
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2021. Diabetes Care. 2021;44(Supplement 1):S1-S232. doi:10.2337/dc21-S000
10. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-1625. doi:10.2337/diabetes.54.6.1615
11. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
12. International Diabetes Federation. IDF Diabetes Atlas - 9th Edition. 2019. Accessed February 2023. Available from: https://www.diabetesatlas.org
13. American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: *Standards of Medical Care in Diabetes-2020*. *Diabetes Care*. 2020;43(Suppl 1):S37-S47. doi:10.2337/dc20-S004
14. Association AD. 6. Glycemic targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Supplement 1):S73-S84. doi:10.2337/dc21-S006
15. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Current Diabetes Reports. 2013;13(6):814-823. doi:10.1007/s11892-013-0432-y
16. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2009;5(3):150-159. doi:10.1038/nrendo.2009.12
17. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. New England Journal of Medicine. 2013;368(17):1613-1624. doi:10.1056/NEJMsa1213829
18. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi:10.2337/dci18-0033
19. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570-2581. doi:10.1001/jama.287.19.2570
20. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine. 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470